New markers and multivariate models for prostate cancer detection.

Area of Science:

• Urology
• Oncology
• Biochemistry

Background:

• Prostate-specific antigen (PSA) has limitations in specificity for prostate cancer (PCa) detection.
• Various molecular forms of PSA, such as free PSA (fPSA) and proPSA, have been explored to improve specificity.
• Emerging serum and urinary markers show potential but require further validation.

Purpose of the Study:

• To evaluate the enhanced specificity of prostate cancer detection using novel serum and urinary biomarkers.
• To assess the utility of multivariate models incorporating new markers for improved PCa diagnosis.
• To analyze the results and potential challenges of integrating these advanced markers.

Main Methods:

• Analysis of molecular forms of PSA (e.g., %fPSA, proPSA) and new serum markers (e.g., EPCA2, ANXA3).
• Evaluation of urinary analytes (e.g., PCA3, TMPRSS2-ERG) collected post-digital rectal examination.
• Development and application of multivariate models, including artificial neural networks (ANN) and logistic regression (LR)-based nomograms.

Main Results:

• New urinary markers show potential for detecting aggressive PCa and reducing unnecessary biopsies.
• Combination of urinary and serum markers with total PSA (tPSA) appears most promising for enhancing specificity.
• Multivariate models incorporating new markers and clinical data generally show an advantage over PSA and %fPSA alone.

Conclusions:

• Novel biomarkers and multivariate models significantly enhance prostate cancer detection specificity.
• Integrating new urinary and serum markers with established methods offers a promising strategy to improve diagnostic accuracy.
• Careful consideration of study results and potential pitfalls is essential for clinical implementation.